25 June,2021 05:28 PM IST | Pune | PTI
Representational Image | File Pic
The first batch of Covovax, a Covid-19 vaccine developed by Novavax Inc, is being manufactured at the Serum Institute of India's Pune facility, SII CEO Adar Poonawalla said on Friday.
"Excited to witness the first batch of Covovax (developed by @Novavax) being manufactured this week at our facility in Pune. The vaccine has great potential to protect our future generations below the age of 18. Trials are ongoing. Well done team @seruminstindia," Poonawalla said in a tweet.
ALSO READ
Mumbai: Delayed adult TB vaccine survey in city likely to begin soon
Israeli strikes in Gaza kill more than a dozen as health workers press on with polio vaccines
Online vaccine management portal U-Win to be launched later this month: Union health secretary
First 100,000 doses of mpox vaccine reach Congo. But it's fraction of what is needed
The first 100,000 doses of mpox vaccine reach Congo. But it's a fraction of what is needed
In March this year, he had said that the clinical trials of Covovax vaccine have begun in India and the company hopes to launch it by September this year. In August 2020, American vaccine company Novavax Inc had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate, in low and middle-income countries and India. In January this year, the Serum Institute had rolled out Covishield vaccine in the country. It had entered into a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine.
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever